In vitro studies reported that ADAM10 and ADAM17 inhibition selectively increases glioma sphere-forming cells but not neural stem cell migration and that the migrated GSCs exhibit a differentiated phenotype, suggesting a role in retaining the cells in the tumorigenic environment in an undifferentiated state [63,64]. The gene discussed is ADAM17; the disease is central nervous system cancer.